IDENTIFICATION OF CLINICALLY RELEVANT GENE VARIANTS IN COLON ADENOCARCINOMA SAMPLES OF UKRAINIAN PATIENTS USING A COMPREHENSIVE CANCER PANEL: A PILOT STUDY

Authors

  • G. GERASHCHENKO Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • R. GULKOVSKYI Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • N. MELNICHUK Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • N. HRYSHCHENKO Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • T. MARCHYSHAK Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • O. MANKOVSKA Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • A. BEZVERKHIY Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • I. KOTUZA Feofaniya Clinical Hospital of the State Management of Affairs, Kyiv, Ukraine
  • L. ROSHA Feofaniya Clinical Hospital of the State Management of Affairs, Kyiv, Ukraine
  • A. KOTUZA Feofaniya Clinical Hospital of the State Management of Affairs, Kyiv, Ukraine
  • Z. TKACHUK Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • V. KASHUBA Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
  • M. TUKALO Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.03.221

Keywords:

NGS, gene variants, colon adenocarcinoma, clinical significance

Abstract

The study aimed to identify the clinically relevant gene variants in colon adenocarcinoma samples of Ukrainian patients using the NGS Comprehensive Cancer Panel (CCP) to implement them conveniently in clinical practice. Methods. We have studied 20 samples of Ukrainian patients with colorectal adenocarcinomas of various differentiation grades. To identify the clinically relevant gene variants, the CCP data were filtered using the Franklin by Genoox database. Results. A total of 79 clinically relevant gene variant alterations (SNVs, INDELs) were found in 28 of 409 genes. The largest number of mutations was found in 3 genes, APC, TP53, and KRAS (16, 14, and 8, accordingly). We revealed 4 variants in PTEN and SMAD4, 3 variants in CHEK2, ERBB2, and PIK3CA genes, and 2 variants in AKT1, ATM, DST, IDH1, and TCF12. Mutations for 7 genes, KRAS, TP53, CHEK2, PTEN, AKT1, APC, and SMAD4, were found in more than 1 tumor tissue sample. Tier 1—2 gene variants rate was about 50% of all genetic variants. The therapeutic significance was found in more than 55% of mutations. Additionally, 11 novel genetic mutations in 9 genes have been identified, including G6PD, APC, DST, SINE1, SMAD2, and FLCN. Conclusions. These data suggest a high level of clinical relevance of the NGS CCP approach. Further confirmation on a larger number of samples and using a deeper analysis by other approaches is required.

References

Fontana F, Anselmi M, Limonta P. Molecular mechanisms of cancer drug resistance: emerging biomarkers and promising targets to overcome tumor progression. Cancers (Basel). 2022;14(7):1614. https://doi.org/10.3390/ cancers14071614

Mansoori B, Mohammadi A, Davudian S, et al. The different mechanisms of cancer drug resistance: A brief review.

Adv Pharm Bull. 2017;7(3):339­348. https://doi.org/10.15171/apb.2017.041

Waarts MR, Stonestrom AJ, Park YC, et al. Targeting mutations in cancer. J Clin Invest. 2022;132(8):e154943. https:// doi.org/10.1172/JCI154943.

Konda P, Garinet S, Van Allen EM, et al. Genome­guided discovery of cancer therapeutic targets. Cell Rep. 2023;42(8):112978. https://doi.org/10.1016/j.celrep.2023.112978

Gammall J, Lai AG. Pan­cancer prognostic genetic mutations and clinicopathological factors associated with sur­ vival outcomes: a systematic review. NPJ Precis Oncol. 2022;6(1):27. https://doi.org/10.1038/s41698­022­00269­5

Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405­424. https://doi. org/10.1038/gim.2015.30

Carvalho NA, Santiago KM, Maia JML, et al. Prevalence and clinical implications of germline pathogenic variants in cancer predisposing genes in young patients across sarcoma subtypes. J Med Genet. 2023;61(1):61­68. https://doi. org/10.1136/jmg­2023­109269

Di Rado S, Giansante R, Cicirelli M, et al. Detection of germline mutations in a cohort of 250 relatives of muta­ tion carriers in multigene panel: impact of pathogenic variants in other genes beyond BRCA1/2. Cancers (Basel). 2023;15(24):5730. https://doi.org/10.3390/cancers15245730

Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations.

Nat Methods. 2010;7(4):248­249. https://doi.org/10.1038/nmeth0410­248.

Choi Y, Sims GE, Murphy S, et al. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688. https://doi.org/10.1371/journal.pone.0046688

Schwarz JM, Cooper DN, Schuelke M, et al. MutationTaster2: mutation prediction for the deep­sequencing age.

Nat Methods. 2014;11(4):361­362. https://doi.org/10.1038/nmeth.2890

Amendola LM, Jarvik GP, Leo MC, et al. Performance of ACMG­AMP variant­interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium. Am J Hum Genet. 2016;98(6):1067­1076. https://doi.org/10.1016/j.ajhg.2016.03.024

Nykamp K, Anderson M, Powers M, et al. Sherloc: a comprehensive refinement of the ACMG­AMP variant classifi­ cation criteria. Genet Med. 2017;19(10):1105­1117. https://doi.org/10.1038/gim.2017.37

Mandelker D, Donoghue M, Talukdar S, et al. Germline­focused analysis of tumour­only sequencing: recom­ mendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2019;30(8):1221­1231. https://doi. org/10.1093/annonc/mdz136

Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24(5):986­998. https://doi. org/10.1016/j.gim.2022.01.001

Tang J, Lam GT, Brooks RD, et al. Exploring the role of sporadic BRAF and KRAS mutations during colorectal can­ cer pathogenesis: A spotlight on the contribution of the endosome­lysosome system. Cancer Lett. 2024;585:216639. https://doi.org/10.1016/j.canlet.2024.216639

Okimoto K, Hirotsu Y, Arai M, et al. Validity of pathological diagnosis for early colorectal cancer in genetic back­ ground. Cancer Med. 2023;12(7):8490­8498. https://doi.org/10.1002/cam4.5596

Zabeti Touchaei A, Vahidi S, Samadani AA. Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis. Eur J Microbiol Immunol (Bp). 2024;14(2):154­165. https://doi. org/10.1556/1886.2024.00015

Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109(8):djw332. https://doi.org/10.1093/jnci/djw332

Downloads

Published

19.12.2024

How to Cite

GERASHCHENKO, G., GULKOVSKYI, R., MELNICHUK, N., HRYSHCHENKO, N., MARCHYSHAK, T., MANKOVSKA, O., … TUKALO, M. (2024). IDENTIFICATION OF CLINICALLY RELEVANT GENE VARIANTS IN COLON ADENOCARCINOMA SAMPLES OF UKRAINIAN PATIENTS USING A COMPREHENSIVE CANCER PANEL: A PILOT STUDY. Experimental Oncology, 46(3), 221–227. https://doi.org/10.15407/exp-oncology.2024.03.221

Issue

Vol. 46 No. 3 (2024): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2024 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)